CAMBRIDGE, England--(BUSINESS WIRE)--Eagle Genomics Ltd. announces today that Anthony Finbow has been appointed to the role of Executive Chairman.
Anthony Finbow has been working since September 2015 in advising Abel Ureta-Vidal (CEO) and the Board of Eagle Genomics in developing the business, in shaping the company’s product vision and in preparing the business for growth. Anthony replaces Alan Barrell in the role, who now becomes a non executive director.
Anthony has achieved success as CEO of a number of intellectual property rich software businesses and has occupied every seat at the board table: Chairman, CEO, CFO, NXD and Investor Director (for both public and private companies).
Anthony commented, “I am delighted to have been invited to become executive chairman at Eagle Genomics at this formative stage in the company’s development. In the short time that I have been involved with the business, we have achieved exciting progress, including the securing of our most significant software sale to date and the development, with launch customers, of a new family of products, to be announced shortly.”
Abel Ureta-Vidal, Founder and CEO commented, “Anthony’s arrival has been transformative for Eagle Genomics. He has been pushing the boundaries of the business and the management team to come up with innovative products opening up unsuspected opportunities. I am happy to have him my side and I’m confident that the coming years will be the most exciting for the Eagle Genomics business. Finally I’d like to thank Alan Barrell for his help and support over the last six years. He has also been instrumental in bringing Anthony on board.”
Alan Barrell commented, “It has been an exciting journey for me with Eagle for six years. I am pleased to remain involved as a director and shareholder. I am especially pleased that Anthony has joined – the company needs someone of his experience and with sufficient time available to support the founders and the excellent team through the next crucial period of scale up and growth.”
In addition, Andrew Muir joins the board of Eagle Genomics as a non-executive director. Andrew is a Director of specialist venture capital fund manager Midven and Fund Principal of the Rainbow Seed Fund.
About Eagle Genomics
Eagle Genomics is a software company helping life sciences companies conducting genomics research to bring new candidate medicines, therapies and products to patients and customers more quickly. Its software solutions exploit smart data science and deep statistics to radically reduce time to complete and cost of research, thus enabling customers to achieve drastic productivity improvements and enable true data driven discovery.
For more information on Eagle Genomics, please visit the company’s website at https://www.eaglegenomics.com/, follow Eagle Genomics on Twitter (@Eaglegen) or call Eagle Genomics at +44 (0)1223 654481
Contacts
Eagle Genomics
Raminderpal Singh
raminderpal.singh@eaglegenomics.com
+44 7719.622.303
https://www.eaglegenomics.com/
Anthony Finbow has been working since September 2015 in advising Abel Ureta-Vidal (CEO) and the Board of Eagle Genomics in developing the business, in shaping the company’s product vision and in preparing the business for growth. Anthony replaces Alan Barrell in the role, who now becomes a non executive director.
Anthony has achieved success as CEO of a number of intellectual property rich software businesses and has occupied every seat at the board table: Chairman, CEO, CFO, NXD and Investor Director (for both public and private companies).
Anthony commented, “I am delighted to have been invited to become executive chairman at Eagle Genomics at this formative stage in the company’s development. In the short time that I have been involved with the business, we have achieved exciting progress, including the securing of our most significant software sale to date and the development, with launch customers, of a new family of products, to be announced shortly.”
Abel Ureta-Vidal, Founder and CEO commented, “Anthony’s arrival has been transformative for Eagle Genomics. He has been pushing the boundaries of the business and the management team to come up with innovative products opening up unsuspected opportunities. I am happy to have him my side and I’m confident that the coming years will be the most exciting for the Eagle Genomics business. Finally I’d like to thank Alan Barrell for his help and support over the last six years. He has also been instrumental in bringing Anthony on board.”
Alan Barrell commented, “It has been an exciting journey for me with Eagle for six years. I am pleased to remain involved as a director and shareholder. I am especially pleased that Anthony has joined – the company needs someone of his experience and with sufficient time available to support the founders and the excellent team through the next crucial period of scale up and growth.”
In addition, Andrew Muir joins the board of Eagle Genomics as a non-executive director. Andrew is a Director of specialist venture capital fund manager Midven and Fund Principal of the Rainbow Seed Fund.
About Eagle Genomics
Eagle Genomics is a software company helping life sciences companies conducting genomics research to bring new candidate medicines, therapies and products to patients and customers more quickly. Its software solutions exploit smart data science and deep statistics to radically reduce time to complete and cost of research, thus enabling customers to achieve drastic productivity improvements and enable true data driven discovery.
For more information on Eagle Genomics, please visit the company’s website at https://www.eaglegenomics.com/, follow Eagle Genomics on Twitter (@Eaglegen) or call Eagle Genomics at +44 (0)1223 654481
Contacts
Eagle Genomics
Raminderpal Singh
raminderpal.singh@eaglegenomics.com
+44 7719.622.303
https://www.eaglegenomics.com/
